IntegraGen announced today that Dana Farber Cancer Institute will use MERCURYTM, IntegraGen's proprietary software, in their analysis and reporting of tumor sequencing data from cancer patients. Dana Farber plans to use MERCURY for the analysis of targeted gene panel sequences, as well as data obtained from exome and whole genome sequencing.

To the press release

---

March 26, 2020

Share :

---

• COVID-19: Measures to protect everyone and ensure your projects run smoothly
• IntegraGen Update - Always open for your projects